Search results for "treatment response"

showing 10 items of 50 documents

Monitoring free serum IgE in severe asthma patients treated with omalizumab

2012

SummaryBackgroundBenefit of treatment with the monoclonal anti-IgE-antibody omalizumab in severe IgE-dependent asthma requires a significant reduction of serum free IgE concentrations. It is unclear if monitoring free serum IgE is clinically meaningful once omalizumab treatment is initiated.MethodsFree IgE and omalizumab serum concentrations were quantified in 22 patients with severe asthma (68% female, 47 ± 11 yrs, mean (±SD) pre-bronchodilator FEV1 62 ± 13%, baseline mean (±SEM) free serum IgE 652 ± 136 ng/ml) treated with omalizumab for 4 months using a Recovery-ELISA.ResultsOmalizumab treatment reduced free serum IgE prior to the second omalizumab injection by 73%, after 16 weeks by 81%…

AdultMalePulmonary and Respiratory MedicineTreatment responsemedicine.medical_specialtySevere asthmaInjections SubcutaneousEnzyme-Linked Immunosorbent AssayOmalizumabOmalizumabTarget rangeAntibodies Monoclonal HumanizedImmunoglobulin EGastroenterologyAnti-asthmatic AgentSerum igeYoung AdultInternal medicinemedicineHumansIn patientAnti-Asthmatic AgentsAgedAsthmabiologybusiness.industryRespiratory diseaseMiddle AgedImmunoglobulin Emedicine.diseaseAsthmaAntibodies Anti-IdiotypicClinical trialTreatment OutcomeFree serum IgEMonoclonalImmunologybiology.proteinFemaleAntibodybusinessmedicine.drugRespiratory Medicine
researchProduct

Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database

2019

ObjectivesA few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response.MethodsWe applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP. Clinical characteristics and treatment response were reviewed for each patient. The Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP.ResultsAt the time of inclusion, 376 (82%) patients had a diagnosis of typical CIDP while 84 …

AdultMaleTreatment responselewis-sumner syndromeAdolescentDatabases FactualDisease durationchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; Surgery; Neurology (clinical); Psychiatry and Mental HealthKaplan-Meier EstimateCIDPcomputer.software_genreDisease courseYoung Adultlewis–sumner syndrome03 medical and health sciences0302 clinical medicineHumansMedicineIn patientChildAgedRetrospective StudiesAged 80 and overchronic inflammatory demyelinating polyradiculoneuropathyRetrospective reviewdistal acquired demyelinating symmetric neuropathyDatabasebusiness.industryPolyradiculoneuropathyMiddle Agedchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndromemedicine.diseasePsychiatry and Mental healthchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; surgery; neurology ; psychiatry and mental healthItalyPolyradiculoneuropathy Chronic Inflammatory Demyelinatingdiagnostic criteriaDisease ProgressionFemaleSettore MED/26 - NeurologiaSurgeryProgression rateNeurology (clinical)CIDP; chronic inflammatory demyelinating polyradiculoneuropathy; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis–sumner syndromebusinesscomputer030217 neurology & neurosurgeryJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

A multi-centre cohort study of short term outcomes of hospital treatment for anorexia nervosa in the UK

2013

Background Individual, family and service level characteristics and outcomes are described for adult and adolescent patients receiving specialist inpatient or day patient treatment for anorexia nervosa (AN). Potential predictors of treatment outcome are explored. Method Admission and discharge data were collected from patients admitted at 14 UK hospital treatment units for AN over a period of three years (adult units N = 12; adolescent N = 2) (patients N = 177). Results One hundred and seventy-seven patients with a severe and enduring illness with wide functional impairment took part in the study. Following inpatient care, physical improvement was moderate/good with a large increase in BMI,…

AdultMalemedicine.medical_specialtyAnorexia NervosaAdolescentSelf-conceptTreatment responseCohort StudiesFeeding and Eating DisordersPatient satisfactionmedicineHumansExpressed emotionPsychiatryInpatientsInpatient carePredictorsbusiness.industrymedicine.diseaseSelf ConceptUnited KingdomTreatmentHospitalizationPsychiatry and Mental healthEating disordersTreatment OutcomeMoodPatient SatisfactionAnorexia nervosa (differential diagnoses)Eating disordersFemalebusinessResearch ArticleCohort studyBMC Psychiatry
researchProduct

Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients

2020

Abstract Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several risk factors, including local epidemiological characteristics, the emergence of fungal resistance and the innate resistance of emerging pathogens, the use of new immunosuppressants, as well as off-target effects of new oncological drugs. The presence of specific host genetic variants and the patient's immune system status may also influence the establishment of an IMI and the outcome of its therapy. Immunological components can thus be expected to play a pivotal role not only in the risk assessment and diagnosis, but also in the treatment of IMI. Cytokines could improve the reliability…

AdultMalemedicine.medical_specialtyTreatment responseAntifungal Agentshemato-oncological malignanciesAspergillosismucormycosis03 medical and health sciencesImmunocompromised HostImmune systemSDG 3 - Good Health and Well-beingInternal medicineNeoplasmsEpidemiologyimmunological statusmedicineHumansIntensive care medicine030304 developmental biologyAgedAged 80 and over0303 health sciencesHematology030306 microbiologybusiness.industryinvasive pulmonary aspergillosishematologyMucormycosisCancerReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseInfectious Diseaseshemato-oncological malignancies; hematology; immunological status; invasive pulmonary aspergillosis; mucormycosisAcademicSubjects/SCI00960FemaleOriginal ArticleRisk assessmentbusinessAcademicSubjects/MED00010Invasive Fungal Infections
researchProduct

Types of Adult Attention-Deficit/Hyperactivity Disorder: A Replication Analysis.

2019

OBJECTIVE Research supports the importance of emotional symptoms in adults with attention-deficit/hyperactivity disorder (ADHD), which are not reflected in the DSM-5 or ICD-10 criteria. The Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) assesses these symptoms, plus inattention, hyperactivity, and impulsivity. This scale allowed us to divide adult ADHD into 2 subtypes in a 2015 publication: ADHD inattentive presentation and ADHD emotional dysregulation presentation. The present study refines this observation using a larger, more diverse sample. METHODS Eight double-blind adult ADHD clinical trials (encompassing 1,490 subjects) were selected because they included assessment…

AdultTreatment responseImpulsivityFactor structurebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineRating scalemental disordersMedicineAttention deficit hyperactivity disorderHumansAffective SymptomsClinical Trials as Topicbusiness.industryAttention deficit disordermedicine.diseaseEmotional dysregulation030227 psychiatryClinical trialPsychiatry and Mental healthAttention Deficit Disorder with Hyperactivitymedicine.symptombusinessFactor Analysis Statistical030217 neurology & neurosurgeryClinical psychologyThe Journal of clinical psychiatry
researchProduct

Primary cutaneous lymphomas in children: A prospective study from the Spanish Academy of Dermatology and Venereology (AEDV) Primary Cutaneous Lymphom…

2021

Background/Objectives Primary cutaneous lymphomas are rare in pediatric patients. The clinical and histopathological manifestations may differ from those in adults. Due to their low frequency and the insidious clinical picture, the diagnosis is usually delayed. The Spanish Primary Cutaneous Lymphoma Registry was initiated in 2016 as a multicenter registry that would allow better insight into the epidemiological, clinical, histopathological, and treatment response characteristics of patients with primary cutaneous lymphomas. Methods We conducted a prospective observational cohort study of primary cutaneous lymphomas in pediatric patients participating in the Spanish Academy of Dermatology an…

AdultTreatment responsemedicine.medical_specialtyVenereologySkin NeoplasmsAdolescentlymphomaDermatologyMycosis FungoidesVenereologyEpidemiologymedicineneoplasms-malignantHumansProspective StudiesRegistriesProspective cohort studyChildtherapy-topicalMycosis fungoidesbusiness.industryPrimary cutaneous lymphomamedicine.diseaseDermatologyLymphomaPediatrics Perinatology and Child HealthbusinessphototherapyCohort studyPediatric dermatologyREFERENCES
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct

Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management.

2013

Endoscopic ultrasonography (EUS) has recently gained a pivotal role in the management of gastric lymphomas, especially in the diagnostic workup. Its accuracy and reliability have overcome those of other imaging techniques, such that it represents an invaluable tool for the management of gastric lymphomas. Although this technique is operator dependent, its application in large series has proved its reliability. Thus, it has generally been considered a useful tool for providing information crucial in deciding the treatment program, especially for mucosa-associated lymphoid tissue (MALT) lymphomas, for which EUS can provide an accurate evaluation of disease extension and treatment response pro…

Cancer Researchmedicine.medical_specialtyTreatment responseDecision MakingEndoscopic ultrasonographyDiseaseGastroenterologyEndosonographyStomach NeoplasmsSubmucosaInternal medicinemedicineHumansNeoplasm Stagingbiologybusiness.industryGastric lymphomaStomachLymphoma Non-HodgkinDisease ManagementHematologyHelicobacter pylorimedicine.diseasebiology.organism_classificationPrognosisdigestive system diseasesPatient managementmedicine.anatomical_structureTreatment OutcomeOncologyRadiologybusinessClinical lymphoma, myelomaleukemia
researchProduct

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS6…

2021

Abstract Introduction : In patients (pts) with multiple myeloma (MM), next generation flow cytometry (NGF) and next generation sequencing have shown an increased capacity to identify the presence of disease and to anticipate patient's prognosis as compared to serum protein immunofixation (IFE). However, both methods rely on bone marrow (BM) samples and it is important to explore alternative techniques applicable in more accessible samples such as peripheral blood. Patients and Methods: Newly diagnosed MM pts enrolled in the PETHEMA/GEM2012MENOS65 trial received six cycles of induction with bortezomib, lenalidomide and dexamethasone (VRD), intensification with high-dose therapy (melphalan or…

Clinical trialTreatment responseChromatographymedicine.diagnostic_testChemistryImmunologymedicineCell BiologyHematologyMass spectrometryBiochemistryFlow cytometryBlood
researchProduct

Abstract # 3128 Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis

2019

Metabolic abnormalities and peripheral inflammation have been increasingly reported in patients at their first episode of psychosis (FEP) and associated with increased mortality. However, the impact of an abnormal metabolic-inflammatory status on the psychiatric outcome of FEP is understudied. This study aimed 1) to combine metabolic and inflammatory variables in factors accounting for an overall metabolic-inflammatory status in FEP patients; 2) to explore the association between these factors and clinical outcome at 1 year. We recruited 43 FEP patients and 50 healthy controls (HC). At baseline (T1) we measured high sensitivity C-reactive protein (hsCRP) as inflammatory biomarker, and body …

First episodePsychosismedicine.medical_specialtyTreatment responsemedicine.diagnostic_testEndocrine and Autonomic Systemsbusiness.industryImmunology1 year follow upmedicine.diseaseBehavioral NeuroscienceFirst episode psychosisInternal medicineMedicineIn patientbusinessLipid profileBody mass indexBrain, Behavior, and Immunity
researchProduct